

01/12/98

13516 U.S. PTO

FEE TRANSMITTAL

(Small Entity)

Complete if Known

Application Number 07/402,450

Filing Date September 1, 1989

First Named Inventor Murakawa

Group Art Unit 1814-1034

Examiner Name Escallan

Total Amount of Payment (\$130.00)

Attorney Docket Number 2124-154

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Kurz

☐ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Charge for the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. ☒ Payment Enclosed: Check

FEE CALCULATION

1. FILING FEE

Fee Description	Fee Code	Fee Paid
<input type="checkbox"/> Utility Filing Fee	201	395
<input type="checkbox"/> Design Filing Fee	206	165
<input type="checkbox"/> Plant Filing Fee	207	270
<input type="checkbox"/> Reissue Filing Fee	208	395
<input type="checkbox"/> Provisional Filing Fee	214	75

SUBTOTAL \$

2. CLAIMS

	Fee from	Extra	below	Fee Paid
Total Claims	- 20 =	x	\$11 =	
Independent Claims	- 3 =	x	41 =	
Multiple Dependent Claims		+	135 =	

SUBTOTAL \$

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Description	Fee Code	Fee Paid
<input type="checkbox"/> Surcharge - late filing fee or oath	205	65
<input type="checkbox"/> Surcharge - late provisional filing fee or cover sheet	227	25
<input type="checkbox"/> Non-English specification	139	130
<input type="checkbox"/> For filing a request for reexamination	147	2,520
<input type="checkbox"/> Requesting publication of SIR prior to Examiner action	112	920
<input type="checkbox"/> Requesting publication of SIR after Examiner action	113	1,840*
<input type="checkbox"/> Extension for reply within first month	215	55
<input type="checkbox"/> Extension for reply within second month	216	200
<input type="checkbox"/> Extension for reply within third month	217	475
<input type="checkbox"/> Extension for reply within fourth month	218	755
<input type="checkbox"/> Extension for reply within fifth month	228	1,030
<input type="checkbox"/> Notice of Appeal	219	155
<input type="checkbox"/> Filing a brief in support of an appeal	220	155
<input type="checkbox"/> Request for Oral Hearing	221	135
<input type="checkbox"/> Petition to institute a public use proceeding	138	1,510
<input type="checkbox"/> Petition to revive -unavoidable	240	55
<input type="checkbox"/> Petition to revive - unintentional	241	660
<input type="checkbox"/> Utility issue fee (or reissue)	242	660
<input type="checkbox"/> Design issue fee	243	225
<input type="checkbox"/> Plant issue fee	244	335
<input checked="" type="checkbox"/> Petitions to the Commissioner	122	130
<input type="checkbox"/> Petitions related to provisional applications	123	50
<input type="checkbox"/> Submission of Information Disclosure Statement	126	240
<input type="checkbox"/> Recording each patent assignment per property (times number of properties)	581	40
<input type="checkbox"/> Filing a submission after final rejection (37 CFR .129(a))	246	395
<input type="checkbox"/> For each additional invention to be examined (37 CFR 1.129(b))	249	395

Other fee (specify)

☐

* Reduced by Basic Filing Fee Paid

SUBTOTAL \$

SUBMITTED BY		Complete (if applicable)	
NAME & REG. NUMBER	E. Anthony Figg, Reg. No. 27,195		
SIGNATURE	DATE	DEPOSIT ACCOUNT USER ID	
<i>E. Anthony Figg</i>	1/9/98		

understanding of the subject matter sought to be patented. Accordingly, applicants respectfully submit this petition in compliance with the Board's directive. A supplemental declaration of the inventor and a check in the amount of \$130.00 to cover the petition fee under 37 C.F.R. § 1.17(i) accompany this petition. The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this paper is provided.

At Example V, at page 12 of the application as filed, reference is made to figures 1, 1A and 1B. These figures did not accompany the application as filed on September 1, 1989. On December 5, 1991, Applicants filed an amendment cancelling from the specification the paragraph referring to the three figures. Applicants submit that none of the figures is necessary to an understanding of the application or for support of any claim. Example V describes an experimental procedure in which peripheral blood lymphocyte RNA from an AIDS patient was amplified using two sets of primers. The first set of primers were designated "HIV A" and "HIV B." The second set of primers were T-cell receptor A and B synthetic oligonucleotides. The first two cycles of PCR amplification employed the enzyme, AMV reverse transcriptase. The following 28 rounds of amplification employed the enzyme, *Thermus aquaticus* DNA polymerase. The amplification products were analyzed by Southern hybridization. The immobilized amplification products were probed with two separate probes. The first was a radiolabelled oligonucleotide designated "HIV C." The second was a T-cell receptor C